Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (295)
- Advertising (25)
- Safety monitoring and information (23)
- Manufacturing (11)
- Scheduling (national classification system) (10)
- COVID-19 (7)
- Clinical trials (6)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Medicinal cannabis hub (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
567 result(s) found, displaying 26 to 50
-
Corporate reportsThe report cards show the progress made by the TGA in the 3 strategies that make up the Action Plan for Medical Devices.
-
Meeting statementsCommunique from the 8th meeting of the WHPWG 30 October 2024
-
Meeting statementsAdvisory Committee on Vaccines meeting statement 52
-
Meeting statementsCommunique from the 2nd meeting of the Human Research Ethics Committee and TGA Clinical Trials Discussion Forum, 1 May 2025
-
Meeting statementsMeeting statement from the 16th Consumer Working Group meeting that took place on 25 March 2025.
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 14 November 2024
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsRead the meeting statement from the meeting of the Advisory Committee on Medical Devices.
-
Corporate reportsFind out about the seasonal influenza vaccines available for the 2025 southern hemisphere season.
-
Meeting statementsCommunique from the meeting of the TGACC
-
Corporate reportsClarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).
-
Meeting statementsRead the meeting statement from 13 February 2025 meeting of the Advisory Committee on Medical Devices.
-
Corporate reportsDetailed statistical information on Therapeutic Goods Administration performance in pre- and post-market activities.
-
Corporate reportsThis report provides information about our regulatory performance for the 2023-24 financial year.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsAdvisory Committee on Vaccines meeting statement 49 for meeting held 2 October 2024
-
Meeting statementsAdvisory Committee on Vaccines Statement 51 for meeting held 5 February 2025
-
Meeting statementsAdvisory Committee on Vaccines meeting statement for meeting 50 held 4 December 2024
-
Meeting statementsMeeting statement from the 15th Consumer Working Group meeting that took place on 8 November 2024.
-
Corporate reportsThis report provides an overview of pharmacovigilance inspection deficiencies in 2022, including a comparison to results from previous reporting periods.
-
Corporate reportsThe findings will inform the need for any risk management actions to ensure public safety.
-
Corporate reportsThis plan outlines our compliance and education priorities for 2024-2025.
-
Meeting statementsRead the meeting statement from 12 December 2024 meeting of the Advisory Committee on Medical Devices.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsCommunique from the 1st meeting of the Human Research Ethics Committee and TGA Clinical Trials Discussion Forum, 27 November 2024